Loyal

Drug development to support longevity in dogs

Loyal logo
21-100 employees
  • Healthcare
  • B2B
  • Enterprise
  • Manufacturing
  • Deep Tech
  • Pets
  • Biology
SoMa, San Francisco, CA

Jump to section

Company mission

To help dogs everywhere live longer, healthier lives.

Our take

People love their dogs, with many owners willing to do almost anything to get more time with their furry companions. Loyal addresses this, by developing drugs that target dog ageing and its associated health challenges.

Leveraging cutting-edge research and advanced scientific methodologies, the company formulates pharmaceuticals that not only extend dogs' lifespans but also improve overall quality of life. By collaborating with leading experts in veterinary medicine and biotechnology, Loyal aims to bring these life-extending treatments to the market, offering hope to pet owners and their beloved companions.

The future of Loyal looks promising, as it leads the way in advancing pet longevity and health. With a strong commitment to innovation and ongoing efforts to gain FDA approval for its drugs, Loyal is all set to transform the pet healthcare industry.

Steph headshot

Steph

Company Specialist at Welcome to the Jungle

Benefits

  • Annual company retreat at beautiful locations across the country (recently: Tahoe, Cape Cod)
  • Full-coverage health insurance — medical, dental, and vision — for you and your dependents
  • Unlimited vacation and paid holidays
  • $1,000 home office equipment stipend
  • $1,200/year learning budget for books, courses, etc
  • $250/month wellness budget for gym, cleaners, spa, food, etc
  • All 3-day weekends are turned into 4-day weekends
  • Paw-ternity leave — adopt a dog and get a day off with your new family member
  • Company equity options grant for new hires

Funding (last 2 of 6 rounds)

Feb 2025

$22m

SERIES B

Mar 2024

$45m

SERIES B

Total funding: $129m

This company has top investors

Leadership

Celine Halioua

(CEO)

Previously the Chief of Staff at The Longevity Fund. They were also a Scientific Consultant at Oisín Biotechnologies and a Researcher of Neuro-oncology at Sanford Burnham Prebys Medical Discovery Institute.